Viral Hepatitis Epidemiology and Prevention Program, The Kirby Institute, UNSW Sydney, Sydney, NSW, 2052, Australia.
Nai Zindagi Trust, 37-38, Beverly Center, Blue Area, Islamabad Capital Territory, 46000, Pakistan.
Harm Reduct J. 2021 May 8;18(1):51. doi: 10.1186/s12954-021-00497-1.
Female sexual partners of men who inject drugs (MWID) living with HIV are at risk of HIV transmission. HIV prevalence estimates among non-drug using female sex partners of MWID are scarce, with no studies documenting HIV incidence. We investigated HIV prevalence and incidence among female spouses of MWID registered at Nai Zindagi Trust (NZT), Pakistan, between 2012 and 2019.
NZT registration and service provision data for female spouses who participated in HIV testing and counselling calculated HIV prevalence and incidence using the person years (PY) method. Cox proportional hazards models identified factors associated with incident infection.
Overall HIV prevalence among female spouses of MWID was 8.5%. Among 3478 HIV-negative female spouses, 109 incident infections were observed, yielding an incidence rate of 1.5/100PY (95% CI 1.2-1.8). Independent predictors of incident infection were registration in Punjab province (AHR 1.73 95% CI 1.13-2.68, p = 0.012) and 1-5 years of education (AHR 1.89 95% CI 1.22-2.93, p = 0.004). Knowledge of HIV at registration was protective against infection (AHR 0.51, 95% CI 0.26-0.99, p = 0.047), along with a MWID spouse who had initiated antiretroviral therapy (ART) (AHR 0.25, 95% CI 0.16-0.38, p < 0.001), while incident infection was inversely associated with number of children (≥ 5 children AHR 0.44 95% CI 0.22-0.88, p = 0.022).
Additional efforts are needed to reduce HIV transmission among female spouses of MWID, including targeted provision of HIV education and access to HIV screening. Interventions that target MWID are also required, including evidence-based drug treatment and access to ART, including support to maximize adherence. Finally, consideration should be given to making HIV pre-exposure prophylaxis available to female spouses at high risk of HIV transmission, particularly young women and those whose husbands are not receiving, or have difficulty adhering to, ART.
与男性注射毒品者(MWID)生活在一起的女性性伴侣如果不使用毒品,也可能面临 HIV 传播的风险。目前,针对非吸毒的 MWID 女性性伴侣的 HIV 流行率估计数据很少,并且没有研究记录 HIV 的发病率。我们调查了 2012 年至 2019 年间在巴基斯坦的 Nai Zindagi Trust(NZT)登记的 MWID 的女性配偶中 HIV 的流行率和发病率。
利用新西兰信托(NZT)的注册和服务提供数据,对参加 HIV 检测和咨询的女性配偶进行计算,采用人年(PY)法计算 HIV 的流行率和发病率。Cox 比例风险模型确定了与感染事件相关的因素。
MWID 女性配偶的总体 HIV 流行率为 8.5%。在 3478 名 HIV 阴性的女性配偶中,观察到 109 例新发感染,发病率为 1.5/100PY(95%CI 1.2-1.8)。新发感染的独立预测因素包括在旁遮普省登记(AHR 1.73,95%CI 1.13-2.68,p=0.012)和接受 1-5 年教育(AHR 1.89,95%CI 1.22-2.93,p=0.004)。在登记时就了解 HIV 情况可以起到预防感染的作用(AHR 0.51,95%CI 0.26-0.99,p=0.047),MWID 配偶开始接受抗逆转录病毒治疗(ART)(AHR 0.25,95%CI 0.16-0.38,p<0.001)也有保护作用,而感染的发生与儿童人数呈反比(≥5 名儿童 AHR 0.44,95%CI 0.22-0.88,p=0.022)。
需要进一步努力降低 MWID 女性配偶的 HIV 传播风险,包括提供针对性的 HIV 教育和进行 HIV 筛查。还需要针对 MWID 的干预措施,包括基于证据的药物治疗和获得 ART,包括支持最大程度地坚持治疗。最后,应考虑为高风险的 HIV 传播的女性配偶提供 HIV 暴露前预防,特别是年轻妇女和那些其丈夫未接受、或难以坚持接受 ART 的妇女。